Scientists Reverse Radiotherapy Resistance in Lung Cancer by Rewiring the Immune Microenvironment

Radiotherapy remains one of the most important weapons against non-small cell lung cancer, the disease that accounts for roughly 85 percent of all lung cancers and carries a bleak prognosis once it reaches advanced stages. Yet despite decades of refinement in dose planning and delivery, a stubborn problem persists: many tumors simply refuse to surrender to the radiation beam, and locoregional relapse after treatment remains alarmingly frequent. A new study published in the Journal of Experimental & Clinical Cancer Research offers one of the most detailed explanations yet for why that happens, and, more importantly, points to a two-pronged strategy for reversing it. The research, led by Sergio Leon and Nerea Otegui of the Program in Solid Tumors at CIMA-University of Navarra in Spain, with Diego Serrano and Alfonso Calvo as senior authors, reveals that radioresistance is not merely a matter of cancer cells becoming intrinsically tougher. It is a coordinated transformation, one that reshapes both the tumor’s own DNA damage machinery and the entire immune landscape surrounding it.

To capture that transformation in motion, the team did something many earlier studies failed to do. Rather than relying on the human cell lines that dominate the radioresistance literature, lines that are poorly suited to immunocompetent systems and therefore blind researchers to the immune dimension of treatment failure, the investigators generated radioresistant isogenic variants of murine lung adenocarcinoma cell lines. Because these variants are genetically matched to their radiation-sensitive parents, any differences that emerge after repeated irradiation can be attributed to adaptive changes rather than pre-existing genetic background. The team then interrogated these paired models using transcriptomics, three-dimensional co-culture systems, and syngeneic mouse models that retain fully functioning immune systems.

The results paint a picture of tumors that have reorganized themselves at multiple levels simultaneously. The radioresistant clones displayed stable adaptations to DNA damage, including enhanced clonogenic survival after irradiation and constitutive activation of DNA damage response pathways, with the ATR pathway, named for the ataxia telangiectasia and Rad3-related kinase, standing out as particularly active. ATR functions as a master regulator of the cellular response to replication stress and DNA damage, and its persistent activation appears to give cancer cells a cushion against the strand breaks that ionizing radiation inflicts. Critically, the clinical relevance of this observation was not left to speculation: analyzing data from non-small cell lung cancer patients, the researchers found that high ATR levels were significantly associated with immunosuppression, linking a tumor-intrinsic survival mechanism to a hostile immune environment in human disease.

The transcriptomic analysis uncovered a second layer of the adaptation. Radioresistant tumors showed altered DNA repair programs alongside a marked downregulation of type-I interferon signaling and innate immune pathways. This is a crucial detail because radiation therapy, in addition to directly damaging DNA, is supposed to function as an in situ vaccine. When tumor cells die from irradiation, they are expected to undergo immunogenic cell death, releasing damage-associated molecular patterns that activate the cGAS-STING sensing axis and other innate pathways, which in turn recruit and activate cytotoxic T cells capable of finishing off survivors. By dampening these pathways, radioresistant tumors essentially mute the alarm system that radiation depends on to alert the immune system, reducing immunogenic cell death and converting what should be an inflammatory dying process into a quiet one.

The consequences of that muting were visible throughout the tumor microenvironment. In syngeneic mice, radioresistant tumors recruited a distinctly immunosuppressive cellular cast: increased numbers of T regulatory cells, M2-like macrophages, and myeloid-derived suppressor cells, along with reduced recruitment of cytotoxic T lymphocytes. These cell types are well-known accomplices of tumor survival, suppressing antitumor immunity through a variety of inhibitory signals and metabolic depletion. The three-dimensional co-culture experiments added a functional confirmation: when immunosuppressive cells were present alongside cancer cells in the same culture, they protected the malignant cells from radiation-induced cytotoxicity. In other words, the immune cells that radioresistant tumors attract are not bystanders. They are active participants in treatment failure, forming a shield that absorbs or suppresses the immune attack that radiation is meant to provoke.

Perhaps the most striking evidence for the centrality of immune suppression came from a transplant experiment of sorts. When the same radioresistant tumors were grown in immunodeficient mice, animals lacking the adaptive and innate immune machinery that normally shields the tumor, they regained their sensitivity to radiotherapy. Stripped of their immunosuppressive entourage, the tumors that had been so resilient in immunocompetent hosts became vulnerable again. This single observation reframes the entire problem of radioresistance: a substantial portion of it is not written into the cancer cell’s genome at all, but is instead conferred by the ecosystem the tumor has cultivated around itself.

That reframing immediately suggested therapeutic possibilities, and the team pursued them with encouraging results. The first approach involved artificially kick-starting innate immunity using agonists of Toll-like receptors, specifically the combination of poly(I:C), which activates TLR3, and R848, which targets TLR7 and TLR8. When these agonists were delivered to radioresistant tumors, they restored antitumor responses and improved the efficacy of radiotherapy, in part through a mechanism centered on the chemokines CXCL9 and CXCL10. These chemokines act as beacons for immune cells, and their induction re-established the recruitment of cytotoxic immune cells into the tumor, effectively rebuilding the alarm system that the radioresistant clones had dismantled. The findings give the study its title and its conceptual core: CXCL9-driven immune rewiring can restore the conditions under which radiation therapy works as intended.

The second approach attacked the problem from inside the cancer cell. Using ceralasertib, a pharmacological inhibitor of ATR, the researchers sensitized radioresistant tumors to radiation, directly undermining the constitutive DNA damage response activation that had given the cells their survival cushion. Together with the innate immune agonists, this establishes a rationale for combined strategies that hit both halves of the radioresistance program at once: stripping away the tumor’s molecular repair capacity with ATR inhibition while simultaneously reigniting the immune recruitment signals that allow radiation to trigger a lasting antitumor response. Neither approach alone represents a complete solution, but the logic of the combination, grounded in the mechanistic findings rather than empirical trial and error, is what distinguishes this work from earlier attempts to sensitize tumors to radiation.

The broader implications reach beyond lung cancer. The study demonstrates that the way radioresistance research is conducted matters: models lacking intact immune systems systematically obscure the contribution of the microenvironment, and this team’s decision to build isogenic immunocompetent models paid off with insights that would have been invisible in conventional systems. For clinicians treating non-small cell lung cancer, the work suggests that markers such as ATR expression and chemokine signatures could eventually help identify patients at risk of locoregional relapse before it occurs, and that combining radiotherapy with TLR agonists or ATR inhibitors deserves serious clinical evaluation. For now, the findings rest on preclinical evidence, and the usual caveats about translation from mice to humans apply. But they offer something that has been in short supply in this field: a mechanistically coherent account of how tumors learn to shrug off radiation, and a map of the vulnerabilities created along the way. As radiotherapy continues to anchor the treatment of lung cancer worldwide, strategies that restore rather than replace its power may prove to be the key to preventing the relapses that have long defied the beam.

Subject of Research: Mechanisms of radioresistance in non-small cell lung cancer involving ATR signaling and immune microenvironment rewiring

Article Title: CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer

Article References: Leon, S., Otegui, N., Redrado, M., Marchena-Perea, E. M., Guruceaga, E., Castro, F., Montuenga, L. M., Oliveira, M. J., Aristu, J. J., Serrano, D., & Calvo, A. (2026). CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03834-z

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03834-z

Keywords: radiotherapy, non-small cell lung cancer, radioresistance, ATR inhibitor, ceralasertib, CXCL9, tumor microenvironment, immunosuppression, TLR agonists, innate immunity, DNA damage response, cancer immunotherapy